National Center for Biomedical Research Information
Log in
Biomedical Literature & Research Abstracts
Advanced SearchBrowse JournalsMeSH IndexClinical TrialsAbout
ClinicalRef › Oncology

Oncology

Results
2 articles
1
Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Previously Untreated NSCLC: KEYNOTE-789 Extended Follow-Up
Chen W, Martinez-Lopez A, O'Brien KM
The New England Journal of Medicine 393: 1567-1580
PMID: 39523187DOI: 10.1056/NEJMoa2501234
clinical-trialFree ArticleNov 8, 2025
Extended 5-year follow-up results from the KEYNOTE-789 trial evaluating pembrolizumab plus platinum-based chemotherapy as first-line treatment for metastatic non-small-cell lung cancer.
pembrolizumabNSCLCimmunotherapyPD-L1KEYNOTE-789
2
Five-Year Outcomes of Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma: The ZUMA-1 Long-Term Follow-Up
Nakamura T, Petrov SI, Williams JR
The Lancet Oncology 26: 901-913
PMID: 39345678DOI: 10.1016/S1470-2045(25)00334-7
abstractFree ArticleJul 22, 2025
This long-term follow-up analysis of the ZUMA-1 trial reports 5-year outcomes of axicabtagene ciloleucel CAR-T cell therapy in adults with relapsed or refractory large B-cell lymphoma.
CAR-T cell therapylymphomaaxicabtagene ciloleucelimmunotherapyZUMA-1